| __timestamp | MannKind Corporation | Ultragenyx Pharmaceutical Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 100244000 | 45967000 |
| Thursday, January 1, 2015 | 29674000 | 114737000 |
| Friday, January 1, 2016 | 14917000 | 183204000 |
| Sunday, January 1, 2017 | 14118000 | 231644000 |
| Monday, January 1, 2018 | 8737000 | 293998000 |
| Tuesday, January 1, 2019 | 6900000 | 357355000 |
| Wednesday, January 1, 2020 | 6248000 | 412084000 |
| Friday, January 1, 2021 | 12312000 | 497153000 |
| Saturday, January 1, 2022 | 19721000 | 705789000 |
| Sunday, January 1, 2023 | 31283000 | 648449000 |
Unleashing the power of data
In the competitive world of pharmaceuticals, innovation is key. Over the past decade, Ultragenyx Pharmaceutical Inc. and MannKind Corporation have demonstrated contrasting approaches to research and development (R&D) spending. From 2014 to 2023, Ultragenyx has consistently increased its R&D investment, peaking at approximately 705% of its 2014 spending by 2022. This commitment underscores their focus on pioneering treatments and therapies. In contrast, MannKind's R&D expenditure has fluctuated, with a notable decline of about 93% from 2014 to 2019, before a modest recovery in recent years. By 2023, MannKind's R&D spending was still only about 31% of its 2014 peak. This divergence highlights Ultragenyx's aggressive pursuit of innovation compared to MannKind's more conservative approach. As the pharmaceutical landscape evolves, these strategies will undoubtedly shape their future trajectories.
R&D Insights: How BeiGene, Ltd. and MannKind Corporation Allocate Funds
Comparing Innovation Spending: United Therapeutics Corporation and Ultragenyx Pharmaceutical Inc.
R&D Spending Showdown: BioMarin Pharmaceutical Inc. vs Ultragenyx Pharmaceutical Inc.
R&D Insights: How Pharming Group N.V. and MannKind Corporation Allocate Funds
Research and Development: Comparing Key Metrics for Ionis Pharmaceuticals, Inc. and MannKind Corporation
Research and Development Expenses Breakdown: Opthea Limited vs MannKind Corporation
Who Prioritizes Innovation? R&D Spending Compared for Amneal Pharmaceuticals, Inc. and MannKind Corporation
Research and Development Investment: Ultragenyx Pharmaceutical Inc. vs CRISPR Therapeutics AG
R&D Spending Showdown: Ultragenyx Pharmaceutical Inc. vs MorphoSys AG
Who Prioritizes Innovation? R&D Spending Compared for Ultragenyx Pharmaceutical Inc. and Amphastar Pharmaceuticals, Inc.
R&D Spending Showdown: Ultragenyx Pharmaceutical Inc. vs Viridian Therapeutics, Inc.
Analyzing R&D Budgets: MannKind Corporation vs BioCryst Pharmaceuticals, Inc.